672 related articles for article (PubMed ID: 32284612)
41. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
Bloomer H; Smith RH; Hakami W; Larochelle A
Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
[TBL] [Abstract][Full Text] [Related]
42. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo.
Psatha N; Georgakopoulou A; Li C; Nandakumar V; Georgolopoulos G; Acosta R; Paschoudi K; Nelson J; Chee D; Athanasiadou A; Kouvatsi A; Funnell APW; Lieber A; Yannaki E; Papayannopoulou T
Blood; 2021 Oct; 138(17):1540-1553. PubMed ID: 34086867
[TBL] [Abstract][Full Text] [Related]
43. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
[TBL] [Abstract][Full Text] [Related]
44. CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells.
Chung JE; Magis W; Vu J; Heo SJ; Wartiovaara K; Walters MC; Kurita R; Nakamura Y; Boffelli D; Martin DIK; Corn JE; DeWitt MA
PLoS One; 2019; 14(1):e0208237. PubMed ID: 30645582
[TBL] [Abstract][Full Text] [Related]
45. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
46. Induction of therapeutic levels of HbF in genome-edited primary β
Mingoia M; Caria CA; Ye L; Asunis I; Marongiu MF; Manunza L; Sollaino MC; Wang J; Cabriolu A; Kurita R; Nakamura Y; Cucca F; Kan YW; Marini MG; Moi P
Br J Haematol; 2021 Jan; 192(2):395-404. PubMed ID: 33216968
[TBL] [Abstract][Full Text] [Related]
47. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
[TBL] [Abstract][Full Text] [Related]
48. Post-Transcriptional Genetic Silencing of
Esrick EB; Lehmann LE; Biffi A; Achebe M; Brendel C; Ciuculescu MF; Daley H; MacKinnon B; Morris E; Federico A; Abriss D; Boardman K; Khelladi R; Shaw K; Negre H; Negre O; Nikiforow S; Ritz J; Pai SY; London WB; Dansereau C; Heeney MM; Armant M; Manis JP; Williams DA
N Engl J Med; 2021 Jan; 384(3):205-215. PubMed ID: 33283990
[TBL] [Abstract][Full Text] [Related]
49. MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A.
Lulli V; Romania P; Morsilli O; Cianciulli P; Gabbianelli M; Testa U; Giuliani A; Marziali G
PLoS One; 2013; 8(4):e60436. PubMed ID: 23593217
[TBL] [Abstract][Full Text] [Related]
50. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
[TBL] [Abstract][Full Text] [Related]
51. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.
Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP
Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313
[TBL] [Abstract][Full Text] [Related]
52. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
53. Genome Editing for the β-Hemoglobinopathies.
Porteus MH
Adv Exp Med Biol; 2017; 1013():203-217. PubMed ID: 29127682
[TBL] [Abstract][Full Text] [Related]
54. CRISPR/Cas9 genome editing in human hematopoietic stem cells.
Bak RO; Dever DP; Porteus MH
Nat Protoc; 2018 Feb; 13(2):358-376. PubMed ID: 29370156
[TBL] [Abstract][Full Text] [Related]
55. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
[TBL] [Abstract][Full Text] [Related]
56. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.
Hoban MD; Cost GJ; Mendel MC; Romero Z; Kaufman ML; Joglekar AV; Ho M; Lumaquin D; Gray D; Lill GR; Cooper AR; Urbinati F; Senadheera S; Zhu A; Liu PQ; Paschon DE; Zhang L; Rebar EJ; Wilber A; Wang X; Gregory PD; Holmes MC; Reik A; Hollis RP; Kohn DB
Blood; 2015 Apr; 125(17):2597-604. PubMed ID: 25733580
[TBL] [Abstract][Full Text] [Related]
57. Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements.
Wang H; Georgakopoulou A; Li C; Liu Z; Gil S; Bashyam A; Yannaki E; Anagnostopoulos A; Pande A; Izsvák Z; Papayannopoulou T; Lieber A
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814708
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.
Wilber A; Hargrove PW; Kim YS; Riberdy JM; Sankaran VG; Papanikolaou E; Georgomanoli M; Anagnou NP; Orkin SH; Nienhuis AW; Persons DA
Blood; 2011 Mar; 117(10):2817-26. PubMed ID: 21156846
[TBL] [Abstract][Full Text] [Related]
59. Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia Major.
Psatha N; Reik A; Phelps S; Zhou Y; Dalas D; Yannaki E; Levasseur DN; Urnov FD; Holmes MC; Papayannopoulou T
Mol Ther Methods Clin Dev; 2018 Sep; 10():313-326. PubMed ID: 30182035
[TBL] [Abstract][Full Text] [Related]
60. In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice.
Li C; Georgakopoulou A; Mishra A; Gil S; Hawkins RD; Yannaki E; Lieber A
Blood Adv; 2021 Feb; 5(4):1122-1135. PubMed ID: 33620431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
